Chronic kidney disease (CKD) and metabolic disorders are driving a major shift in clinical diagnostics—accelerating the transition toward automated, high-precision renal testing.
Valued at USD 632.36M in 2022, the global creatinine assay market is projected to reach USD 878.00M by 2029, growing at a steady 4.80% CAGR.
Key growth catalysts:
• Shift from traditional Jaffe methods to high-specificity en... moreChronic kidney disease (CKD) and metabolic disorders are driving a major shift in clinical diagnostics—accelerating the transition toward automated, high-precision renal testing.
Valued at USD 632.36M in 2022, the global creatinine assay market is projected to reach USD 878.00M by 2029, growing at a steady 4.80% CAGR.
Key growth catalysts:
• Shift from traditional Jaffe methods to high-specificity enzymatic assays
• Rising adoption of automated clinical chemistry analyzers and point-of-care (POCT) cartridges
• Escalating prevalence of diabetes, hypertension, and age-associated renal complications
• Expansion of preclinical drug toxicity screening in biopharma pipelines
How is your diagnostic or clinical research team adapting to higher demand for interference-free renal biomarkers? 🧪
